As someone who has witnessed the transformative impact of innovative cancer treatments, I understand how crucial it is to find a partner that combines expertise, compassion, and cutting-edge technology. At GoBroad, we specialize in adoptive cell therapy, a groundbreaking approach that empowers the immune system to fight cancer with precision and resilience. Our mission is to deliver personalized, research-driven care, leveraging our unique position as a clinical-oriented innovation platform to offer hope to patients facing complex hematologic and solid tumor diagnoses.

About GoBroad: Where Patient Needs Drive Innovation

Founded in 2017, GoBroad Healthcare Group (GHG) has always placed “The Needs of the Patient Come First” at the heart of everything we do. As a pioneer of the research-oriented “Academic Research Organization (ARO)” model in China, we’ve built a network of seven hospitals across Beijing, Shanghai, and Guangzhou, offering nearly 1,500 beds dedicated to advancing treatments for challenging diseases. Our focus on adoptive cell therapy stems from our commitment to bridging clinical discovery with practical application, ensuring patients have access to therapies that harness the immune system’s natural cancer-fighting abilities. Whether through chimeric antigen receptor (CAR)-T cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, or other specialized approaches, we design treatments that target each patient’s unique biology, backed by a multidisciplinary team of experts with deep experience in cellular immunotherapy.

Tailored Adoptive Cell Therapy for Individualized Cancer Care

One of the greatest strengths of adoptive cell therapy is its ability to be customized to each patient’s needs. At GoBroad, we start with thorough diagnostic evaluations, using advanced genetic sequencing and molecular profiling to identify the most suitable cellular targets. For example, the CAR-T cell therapy we offer is designed to genetically engineer a patient’s own T cells to recognize specific cancer antigens, such as CD19 in B-cell malignancies, enabling them to attack tumor cells with precision. This approach has shown remarkable efficacy in relapsed or refractory cases, including hematologic cancers like acute lymphoblastic leukemia and lymphoma, where traditional treatments may fall short. By focusing on autologous and allogeneic cell sources, we ensure each treatment plan is as unique as the patient, maximizing the potential for durable remissions while minimizing systemic side effects.

Collaborative Expertise for Complex Cases

Fighting cancer requires a team, and our multidisciplinary approach to adoptive cell therapy brings together hematologists, oncologists, immunologists, and laboratory scientists to create integrated care pathways. From the moment a patient arrives, our experts collaborate to assess eligibility, design treatment protocols, and monitor progress through every stage—from cell collection and engineering to infusion and post-treatment recovery. This teamwork is especially critical in managing the unique challenges of cellular therapies, such as cytokine release syndrome or tumor microenvironment interactions. For instance, our specialists work closely with patients to optimize preconditioning regimens, ensuring the body is prepared to support the infused cells, while our supportive care teams address any treatment-related symptoms to enhance the quality of life. This coordinated effort ensures that patients receive not just a therapy, but a comprehensive plan designed for their specific needs.

Innovation and Research: Pushing the Frontiers of Adoptive Cell Therapy

As a research-driven organization, GoBroad is constantly exploring new frontiers in adoptive cell therapy through clinical trials and partnerships with global institutions. We are at the forefront of implementing novel techniques, such as “armored” CAR-T cells that secrete cytokines to enhance anti-tumor activity within the tumor microenvironment, or combining TIL therapy with targeted agents to overcome resistance in solid tumors. Our Phase I clinical trial wards and central laboratory facilitate the translation of benchside discoveries into bedside applications, offering patients early access to emerging treatments. By integrating data intelligence and advanced analytics, we also refine our approaches to improve cell manufacturing, expand donor availability, and predict treatment responses, ensuring our therapies remain at the cutting edge of medical science.

Conclusion

Choosing adoptive cell therapy means choosing a path that works with your body’s own defenses, and at GoBroad, we’re committed to guiding you every step of the way. Our focus on personalized care, collaborative expertise, and innovative research makes us a leader in cellular immunotherapy, dedicated to helping patients with even the most complex cases find new hope. Whether you’re considering CAR-T for a relapsed hematologic cancer or exploring TIL therapy for a solid tumor, we’re here to provide the expertise, compassion, and cutting-edge solutions you deserve. Trust in our legacy of putting patients first—because at GoBroad, your journey to healing is our highest priority.